Literature DB >> 363377

Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion.

B A Chabner, R G Stoller, K Hande, S Jacobs, R C Young.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 363377     DOI： 10.3109/03602537808993779

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN： 0360-2532            Impact factor:   4.518


× No keyword cloud information.
  7 in total

1.  All half-lives are wrong, but some half-lives are useful.

Authors:  J G Wright; A V Boddy
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results.

Authors:  R B Jones; C E Myers; A M Guarino; R L Dedrick; S M Hubbard; V T DeVita
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Authors:  V J Wiebe; C C Benz; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 4.  Molecular relation between biological stress and carcinogenesis.

Authors:  Katarzyna Rakoczy; Wojciech Szlasa; Natalia Sauer; Jolanta Saczko; Julita Kulbacka
Journal:  Mol Biol Rep       Date:  2022-05-24       Impact factor: 2.742

5.  The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits.

Authors:  H Iven; H Brasch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.

Authors:  S Monjanel; J P Rigault; J P Cano; Y Carcassonne; R Favre
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  The effects of diltiazem on methotrexate-induced nephrotoxicity.

Authors:  G Deray; D Khayat; P Cacoub; R Bourbouze; L Musset; A Baumelou; C Jacquillat; C Jacobs
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.